New therapies for chronic hepatitis C virus infection
Related Experiment Video
Updated: Aug 29, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Anouk Dev1, Keyur Patel, John G McHutchison
1Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA.
Abstract:
Chronic hepatitis C infection is associated with significant morbidity and mortality in addition to substantial social and health-related costs. Since the identification of the virus and determination of the HCV genome over a decade ago, considerable progress has been made in the treatment of chronic hepatitis C infection. However, the current standard combination of interferon-based therapies and ribavirin is effective in only 50% of patients. In addition, this combination is expensive, requires lengthy periods of administration, and is associated with significant side effects. Furthermore, no effective preventive measure, such as vaccination, is currently available. A number of newer therapies, including protease and helicase inhibitors, ribozymes, antisense therapies, and therapeutic vaccines, are in preclinical and clinical development and may significantly enhance existing therapeutic options for the future.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Chronic Pancreatitis II: Collaborative Care
Assessment:
